Cannabinoids in multiple sclerosis - Therapeutically reasonable?;Cannabinoide bei multipler sklerose - Therapeutisch sinnvoll?

Fortschritte der Neurologie Psychiatrie

Volumn 73, Issue 8, 2005, Pages 463-469

  Trebst, Corrina ^a   Stangel, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; TETRAHYDROCANNABINOL;

ANALGESIA; ARTICLE; CLINICAL TRIAL; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; MYALGIA; NEUROPROTECTION; NONHUMAN; NYSTAGMUS; SPASTICITY; TREMOR;

CANNABINOIDS; CANNABIS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROPROTECTIVE AGENTS; PAIN; PHYTOTHERAPY;

EID: 23844463752     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830119     Document Type: Article

References (41)

1. Frohne D, Jensen U. Systematik des Pflanzenreichs unter besonderer Berücksichtigung chemischer Merkmale und pflanzlicher Drogen. Stuttgart-New York: Gustav Fischer Verlag, 1985
2. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. Ann Chem Soc 1964; 86: 1646-1647
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65
5. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990; 87: 1932-1936
6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202
7. Grotenhermen F. Some practice-relevant aspects of the pharmacokinetics of THC. Forsch Komplementarmed 1999; 6 Suppl 3: 37-39
8. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989; 23: 73-81
9. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994; 28: 209-214
10. Achiron A, Miron S, Lavie V, Margalit R, Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000; 102: 26-31
11. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23: 2511-2516
12. Croxford JL, Miller SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest 2003; 111: 1231-1240
13. Killestein J, Uitdehaag BM, Polman CH. Cannabinoids in multiple sclerosis: do they have a therapeutic role? Drugs 2004; 64: 1-11
14. Killestein J, Hoogervorst EL, Reif M, Blauw B, Smits M, Uitdehaag BM, Nagelkerken L, Polman CH. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J Neuroimmunol 2003; 137: 140-143
15. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38: 44-48
16. Baker D, Pryce G. The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs 2003; 12: 561-567
17. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285
18. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901
19. Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 2002; 11: 1365-1374
20. Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, Guaza C. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002; 22: 9742-9753
21. Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001; 78: 613-625
22. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998; 95: 8268-8273
23. Stelt M van der, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001; 21: 6475-6479
24. Hansen HH, Azcoitia I, Rons S, Romero J, Garcia-Segura LM, Ramos JA, Hansen HS, Fernandez-Ruiz J. Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 2002; 82: 154-158
25. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, Rothwell NJ. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003; 23: 6470-6474
26. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126: 2191-2202
27. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di MV. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-302
28. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87
29. Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980; 21: 81-85
30. Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236: 120-122
31. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996; 34: 446-452
32. Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21: 413S-416S
33. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50
34. Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994; 55: 324-328
35. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-1407
36. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29
37. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-1526
38. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-16
39. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13: 669-671
40. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62: 1105-1109
41. Schon F, Hart PE, Hodgson TL, Pambakian AL, Ruprah M, Williamson EM, Kennard C. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999; 53: 2209-2210